Professor James Larkin is a Consultant Medical Oncologist specialising in the treatment of melanoma and cancers of the kidney.
Professor Larkin took a first in Natural Sciences from Cambridge University and undertook clinical training at Oxford University, qualifying in 1996. He underwent general medical training in London and in 2001 won a Medical Research Council Fellowship for a Clinician, carrying out laboratory research at The Institute of Cancer Research, London, which led to the award of a PhD. He completed specialist training at The Royal Marsden and was appointed a Consultant in 2008.
His research interests involve trying to understand cancer and its consequences better, as well as developing improved treatments, particularly with targeted therapies and immunotherapies. He has served as UK and Global Chief Investigator for a number of clinical trials in melanoma and kidney cancer, many leading to the approval of new drugs for the treatment of advanced disease. He has been awarded research grants from bodies including Cancer Research UK, the Wellcome Trust and the European Framework Programme 7.
He is a past National Institute for Health Research (NIHR) National Specialty Lead for Early Phase Oncology Trials, as well as a past Chair of both the NCRI Renal Cancer Clinical Studies Group and The Royal Marsden/ICR Committee for Clinical Research. He is currently Chair of the CRUK Clinical Research Monitoring Panel, Vice Chair of the CRUK Clinical Research Committee and Lead of the Uncommon Cancers Theme at The Royal Marsden/ICR Biomedical Research Centre. In 2018 he was elected as a Fellow of the Academy of Medical Sciences.
He serves as a medical advisor to the patient advocacy group Melanoma UK, is a trustee of the Kidney Cancer Support Network and serves on the Medical Advisory Board of the International Kidney Cancer Coalition.